Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

Saved in:
Bibliographic Details
Published inBlood cancer journal (New York) Vol. 6; no. 7; p. e448
Main Authors Jacobus, S J, Rajkumar, S V, Weiss, M, Stewart, A K, Stadtmauer, E A, Callander, N S, Dreosti, L M, Lacy, M Q, Fonseca, R
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.07.2016
Springer Nature B.V
Nature Publishing Group
Subjects
692/308
692/308/2779/777
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomedical and Life Sciences
Biomedicine
Bortezomib - administration & dosage
Bortezomib - adverse effects
Cancer Research
Consolidation Chemotherapy - adverse effects
Consolidation Chemotherapy - methods
Dexamethasone - administration & dosage
Dexamethasone - adverse effects
Female
Hematology
Humans
Induction Chemotherapy - methods
Lenalidomide
Letter to the Editor
Male
Middle Aged
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Multiple Myeloma - pathology
Oncology
Salvage Therapy
Survival Analysis
Thalidomide - administration & dosage
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Correspondence-3
content type line 23
ObjectType-Undefined-4
ISSN:2044-5385
2044-5385
DOI:10.1038/bcj.2016.55